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Abstract
Background Unloading/disuse induces skeletal muscle atrophy in bedridden patients and aged people, who cannot prevent
it by means of exercise. Because interventions against known atrophy initiators, such as oxidative stress and neuronal NO syn-
thase (nNOS) redistribution, are only partially effective, we investigated the involvement of melusin, a muscle-specific integrin-
associated protein and a recognized regulator of protein kinases and mechanotransduction in cardiomyocytes.
Methods Muscle atrophy was induced in the rat soleus by tail suspension and in the human vastus lateralis by bed rest.
Melusin expression was investigated at the protein and transcript level and after treatment of tail-suspended rats with atrophy
initiator inhibitors. Myofiber size, sarcolemmal nNOS activity, FoxO3 myonuclear localization, and myofiber carbonylation of
the unloaded rat soleus were studied after in vivo melusin replacement by cDNA electroporation, and muscle force, myofiber
size, and atrogene expression after adeno-associated virus infection. In vivo interference of exogenous melusin with dominant-
negative kinases and other atrophy attenuators (Grp94 cDNA; 7-nitroindazole) on size of unloaded rat myofibers was also
explored.
Results Unloading/disuse reduced muscle melusin protein levels to about 50%, already after 6 h in the tail-suspended rat (P
< 0.001), and to about 35% after 8 day bed rest in humans (P < 0.05). In the unloaded rat, melusin loss occurred despite of
the maintenance of β1D integrin levels and was not abolished by treatments inhibiting mitochondrial oxidative stress, or nNOS
activity and redistribution. Expression of exogenous melusin by cDNA transfection attenuated atrophy of 7 day unloaded rat
myofibers (31%), compared with controls (48%, P = 0.001), without hampering the decrease in sarcolemmal nNOS activity
and the increase in myonuclear FoxO3 and carbonylated myofibers. Infection with melusin-expressing adeno-associated virus
ameliorated contractile properties of 7 day unloaded muscles (P ≤ 0.05) and relieved myofiber atrophy (33%) by reducing
Atrogin-1 and MurF-1 transcripts (P ≤ 0.002), despite of a two-fold increase in FoxO3 protein levels (P = 0.03). Atrophy atten-
uation by exogenous melusin did not result from rescue of Akt, ERK, or focal adhesion kinase activity, because it persisted after
co-transfection with dominant-negative kinase forms (P < 0.01). Conversely, melusin cDNA transfection, combined with 7-
nitroindazole treatment or with cDNA transfection of the nNOS-interacting chaperone Grp94, abolished 7 day unloaded
myofiber atrophy.
Conclusions Disuse/unloading-induced loss of melusin is an early event in muscle atrophy which occurs independently from
mitochondrial oxidative stress, nNOS redistribution, and FoxO3 activation. Only preservation of melusin levels and sarcolem-
mal nNOS localization fully prevented muscle mass loss, demonstrating that both of them act as independent, but complemen-
tary, master switches of muscle disuse atrophy.
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Introduction
Muscle disuse or reduced load, such as occurring to antigrav-
ity muscles in bedridden patients, represents a major cause
of skeletal muscle atrophy1,2. Among the factors responsible
for loss of muscle mass and force, a major role has been at-
tributed to the neuronal NO synthase (nNOS) isoform, whose
changes in subcellular distribution result in decreased activity
of the enzyme at its physiological subsarcolemmal site and in-
creased sustained activity in the myoplasm.3–6 A recent study
from this laboratory further demonstrated that nNOS redis-
tribution occurs before the appearance of muscle atrophy
and shortly after the exposure to disuse/unloading, that is,
after a 6 h unloading bout in the rat soleus muscle and a 8
day bed rest in humans, and is required for the nuclear trans-
location of the “atrogene” transcription factor FoxO3a.7
The unloading-induced involvement of nNOS/FoxO3 path-
way may be prevented by counteracting oxidative stress,
both by using generic or mitochondrial-specific anti-
oxidants4,7,8 or by promoting the interaction of nNOS mole-
cules with the endoplasmic reticulum chaperone
Grp94/gp96, which improves nNOS maintenance at the sar-
colemma.5,9 Nevertheless, the adoption of these counter-
measures did not fully abolish unloading-induced myofiber
atrophy.5,8,9 Consistently, a slight, but significant, degree of
myofiber atrophy was observed even when 7–15 day
hindlimb unloading was performed after knocking out nNOS
or inhibiting its enzyme activity using 7-nitroindazole (7-NI)3,5.
The partial anti-atrophic effects obtained by targeting
unloading-induced nNOS redistribution or activity strongly
suggest that other pathways, in addition to the one involving
nNOS/FoxO3/Grp94, are determinant in the development of
disuse/unloading-induced muscle atrophy. Therefore, the
aim of the present study was to investigate the signal trans-
duction pathway bound to the widespread mechanosensitive
receptor integrins, focusing on the muscle-specific transducer
melusin.
Melusin is a chaperone protein expressed specifically in
cardiac and skeletal muscles. It consists of two N-terminal
cysteine-rich and histidine-rich domains: a CS domain (pecu-
liar of cysteine-rich and histidine-rich domains and Sgt1 pro-
teins)10 and a C-terminal Ca2+-binding domain, rich in
aspartic and glutamic acid residues.11 Melusin has been
found to interact with the cytoplasmic region of β1 integrin
through its CS domain11 and to transduce protective signals
in the myocardium in response to mechanical stress induced
by pressure overload12 or myocardial infarction,13,14 promot-
ing compensatory left ventricle hypertrophy and cardiomyo-
cyte survival.15–17 Indeed, mechanical stress activates
specific signal transduction pathways in cardiomyocytes, such
as the MAPK and the phosphoinositide 3-kinase (PI3K)/Akt
pathways, able to induce a compensatory hypertrophy, cru-
cial in coping with the increased workload. In cardiomyocytes
melusin interact with a number of signalling proteins working
in these pathways, including the focal adhesion kinase (FAK),
the MAPK scaffold protein IQGAP1, the mitogen activated
protein kinases c-Raf, MEK1/2, ERK1/2,18 and PI3K.19
Melusin is also expressed in skeletal muscles; however, its
function in this context has been poorly investigated so far.
Early studies indicated that melusin expression is regulated
during skeletal muscle development, becoming detectable
in embryo limbs at 15 days of gestation and reaching a peak
in newborn muscles. In accordance with a possible role in
myogenesis, melusin expression is upregulated during muscle
regeneration after trauma.12 Moreover, melusin has been
found overexpressed in muscles from limb-girdle muscular
dystrophy type 2 patients, where it regulates β1D integrin
isoform expression.20
By investigating rat and human skeletal muscles after short
and long periods of unloading/bed rest, here we identify
melusin as a new and early disuse target. The rat tail suspen-
sion model was further used to monitor melusin expression
after exposure to muscle atrophy attenuators such as 7-
NI,3,5 or curcumin, which upregulates Grp94/gp96,9 or
MitoTEMPO, which inhibits mitochondrial-derived oxidative
stress and maintains sarcolemmal nNOS activity,7 as well as
to evaluate the effects of exogenus melusin replacement,
by means of in vivo transfection and viral infection. In vivo
transfections allowed to compare melusin-transfected
myofibers with untransfected ones in the same muscle sec-
tion concerning myofiber cross-sectional area (CSA), sarco-
lemmal nNOS activity by means of histochemistry for
NADPH-diaphorase, FoxO3 nuclear localization, and myofiber
carbonylation by means of DNPH adducts. In vivo melusin
cDNA transfection was further used during unloading in com-
bination with 7-NI treatments or other constructs, such as
dominant-negative (DN) forms of the melusin-interacting ki-
nases, or other pro-trophic players, such as the Grp94/gp96
chaperone. Infections with adeno-associated virus (AAV) cod-
ing for melusin allowed to investigate whether unloaded
muscles preserved contractility, in addition to myofiber CSA,
composition in fiber types, myosin heavy chains, levels of
atrogene transcripts, and FoxO3 and kinase proteins.
The combination of these approaches demonstrates here
that melusin is required to maintain mass and force of
unloaded muscle. Interestingly, unloading-induced melusin
loss is not rescued by known atrophy attenuators, and
melusin replacement appears to counteract atrophy
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independently from both integrin-downstream signalling




Exogenous melusin expression was achieved by expressing
human melusin cDNA added with a c-myc tag at the amino-
terminus, either subcloned in a pCEP plasmid or in the AAV
9 (AAV-MEL).21 Empty plasmid (EV) and AAV 9 (AAV-EV) were
used as controls.
Plasmids for DN non-receptor kinases were provided from
Addgene: (i) HA-Akt-DN (plasmid 16243) codifies for a mouse
Akt variant, which is catalytically inactive due to K179M sub-
stitution at the ATP-binding site and was effective with both
rat and human cells22–24; (ii) pcDNA3-HA-ERK2 D319N (plas-
mid 8979) codifies for a rat ERK2 variant with a mutation
preventing the docking (D)-domain-dependent ERK binding
(D319N) to substrates25; and (iii) pEGFP-RapR-FAK-YM-KD
(plasmid 25929) codifies for a murine DN-FAK form, contain-
ing the kinase dead mutation D546R, which was also effective
in human cells.26
Plasmid pT94, a bicistronic vector containing rabbit Grp94
and GFP cDNAs,27 and the corresponding empty vector pT,
expressing GFP only (Invitrogen), were also used.
Rat hindlimb suspension
About 136 six week old female Wistar rats were used in the
study. Rats entered in each experimental protocol in small
groups (n = 8–9 in total) and were randomly selected for stan-
dard caging (n = 2–3) or hindlimb unloading (n = 6) using the
tail suspension model.5,7,9,28 The protocol was performed fol-
lowing the recommendations provided by the European Con-
vention for the protection of Vertebrate Animals used for
Experimental and Scientific purposes (Council of Europe num-
ber 123, Strasbourg, 1985) and authorized by the Animal
Ethics Committee of the University of Padova and the Italian
Health Ministry (authorizations103/2007B and 502/2015PR).
Each animal was weighed before and after the suspension pe-
riod. Sacrifice was performed from 6 h to 15 days after entry
in the unloading experimental protocol, and soleus muscles
were excised, weighed, and frozen in liquid nitrogen, immedi-
ately or after muscle mechanics analyses. Samples were
stored at 80 °C.
Several different experimental protocols combined stan-
dard caging and hindlimb unloading to either pharmacologi-
cal treatments or in vivo gene transfer, that is, direct
injection in the soleus muscle of plasmids or AAV particles,
or both pharmacological treatments and plasmid injection.
Data concerning number of animals and soleus muscles,
together with body and absolute and normalized muscle
weight, were reported in Supporting Information, Table S1,
except for data relative to plasmid-injected muscles, because
of possible flaws on muscle weight due to the transfection
procedure.
In vivo plasmid transfection
Plasmid transfection was performed as previously described5
on about 65 rats, that is, by injecting constructs in the ex-
posed soleus muscle, bilaterally, and applying a train of six
20 ms electrical impulses at 209 V/cm on the closed wounds.
The day after, animals were randomly selected for tail sus-
pension for 7 days or let free to ambulate.
The following constructs were used for soleus muscle
transfections: (i) about 50 μg of melusin cDNA or EV were
co-injected with 30 μg of pT bilaterally in the soleus muscles
of 32 rats, which were then subdivided in four different
groups corresponding to (a) freely ambulating animals
transfected with EV (n = 5); (b) freely ambulating animals
transfected with melusin cDNA (n = 5); (c) hindlimb-unloaded
animals transfected with EV (n = 11); and (d) hindlimb-
unloaded animals transfected with melusin cDNA (n = 11);
(ii) about 50 μg of each plasmid codifying for DN forms of
Akt or ERK2 or FAK were injected in one soleus and in combi-
nation with 50 μg melusin cDNA in the contralateral one in 15
rats (five rats for each DN-kinase plasmid), which were tail-
suspended for 7 days; (iii) about 50 μg of plasmids codifying
for melusin combined either with 50 μg of plasmid pT94 or
with pT one were injected in each soleus of the same rat. This
procedure involved eight rats, which were then tail-
suspended for 7 days.
In vivo adeno-associated virus infections
Rats used for AAV infections were listed in Supporting Infor-
mation, Table S1. After amplification in HEK293 cells, about
1 × 1010 MOI of AAV-MEL or AAV-EV were injected bilaterally
in soleus muscles of 4 week old female rats. A group of rats
was sham infected by injecting saline only. From 3 weeks to
15 days after, rats from each group were randomly selected
for 7 day tail suspension or standard caging.
Pharmacological treatments
A group of rats listed in Supporting Information, Table S1,
was treated with 7-NI (Sigma) or the corresponding vehicle
(peanuts oil) by intraperitoneal injection, as previously de-
scribed.5,9 Treatment started the day before tail suspension
and was repeated daily. The soleus muscles of two groups
of five rats (one group treated with 7-NI and the other with
vehicle) were additionally transfected with 50 μg of melusin,
and rats were exposed the subsequent day to hindlimb
unloading for 7 days.
Still available frozen ambulatory and unloaded muscles ob-
tained from rats treated with curcumin or MitoTEMPO (n of
muscles = 18 and 10, respectively, including those obtained
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from vehicle-treated rats) were used to determine melusin
protein levels. Data concerning these experimental groups
were already published .7,9
Human biopsies
Biometric data of young male participants to the bed rest
campaign organized in July 2007 at the Orthopaedic Hospital
of Valdoltra (Koper, SLO), and details on ethical permission
have been already published.7,28 Bed rest was performed
without head-down tilt for 5 weeks. Biopsies were obtained
from the vastus lateralis muscles of each participant at each
of the following time points, T0, T8, and T35, corresponding
to days after the bed rest start, frozen in liquid nitrogen,
and stored at 80 °C. Although the programme included 10
participants, complete three-biopsy sets were available only
from eight subjects. Previous morphometric analyses demon-
strated the presence of about 20% muscle atrophy in T35 bi-
opsies compared with pre-bed rest values, whereas no
statistically significant reduction of myofiber size was de-
tected in T8 ones.7,28
Western blot
Whole homogenates were prepared by dissolvingmuscle cryo-
sections as previously described .7 Equal amounts of proteins
were separated by electrophoresis in reducing and denaturing
10% polyacrylamide gels and transferred to nitrocellulose in
the presence of methanol. After saturation, blot strips were in-
cubated with anti-melusin mouse monoclonal antibody (mAb)
clone C3 and anti-β1D integrin rabbit polyclonal antibody
(pAb), as previously described.18,29 Anti-FoxO3 rabbit pAb
(Sigma) and anti-total FAK mouse mAb (clone 2A7, Millipore)
were also used. Relative protein amount was calculated after
normalization of the densitometric signal to the corresponding
amount of serum albumin (SA), for rat muscle, and of actin, for
human biopsies, after staining with Red Ponceau or incubation
with anti-GAPDH mouse mAb antibody clone 71.1 (Sigma).
Staining for P-Akt (Ser473) and total Akt, and P-ERK
(Thr202/-Tyr204) and ERK was performed using appropriate
antibodies (Cell Signaling). Relative amount of the phosphory-
lated protein was calculated after normalization with the den-
sitometric signal of total kinase immunoreactivity. Relative
amount of kinases was calculated after normalization with ei-
ther SA or GAPDH, as described earlier.
Quantitative real time PCR
Total RNA from muscles was isolated using Trizol Reagent
(Thermo Fisher Scientific), following the manufacturer’s in-
structions. RNA was reverse transcribed by using the high ca-
pacity cDNA reverse transcription kit (Applied Biosystem).
Gene expression was evaluated using specific primers de-
signed for Itgb1bp2, Atrogin, MuRF-1, FoxO1, Foxo3a, and
Gapdh as endogenous control (see Supporting Information,
Table S2). The relative quantity of gene expression was
analysed with SDS RQ Study software (Applied Biosystem).
Morphometric analyses
Double immunofluorescence and confocal microscopy
Longitudinal cryosections from ambulatory and unloaded so-
leus muscles were fixed with 4% buffered paraformaldehyde
for 30 min at RT, quenched in bovine serum albumin 1% in
phosphate-buffered saline added with 1% goat serum and in-
cubated overnight at RT with anti-β1D integrin pAb29 and
anti-melusin mAb. After extensive rinses, sections were incu-
bated with a mixture of Alexa 568 and 488 secondary anti-
bodies (Invitrogen) diluted in bovine serum albumin 0.5% in
phosphate-buffered saline and preadsorbed with rat serum
to eliminate species cross-reactivity. Sections were analysed
at the confocal microscope Leitz SP5 (Leica Microsystem)
using sequential scanning with Helium 485 and Argon 288 la-
sers. Images were collected at 1024 × 1024 pixels after
Kalman 4 normalization.
Transverse cryosections from 7 days tail-suspended rats,
co-transfected with melusin cDNA or EV together with the
GFP-expressing construct pT or infected with AAV-MEL or
AAV-EV, were stained with rabbit anti-dystrophin pAb
(Abcam) and/or with mouse anti-myc mAb clone 9E10 or with
anti-FoxO3 rabbit pAb (Sigma). In this last case, to distinguish
myofiber nuclei from interstitial ones, sections were doubly
labelled with anti-α sarcoglycan mouse mAb (Monosan) and
nuclei counterstained with DAPI, as previously described.5
Slides were observed with a Leitz Axioplan microscope
equipped for epifluorescence optics, and data were collected
from high magnification micrographs. At least 50 myofiber
nuclei were identified for each fiber group per muscle. Per-
centage of FoxO3-positive nuclei was calculated separately
on the total number of counted myonuclei in transfected or
untransfected myofibers.
Immunohistochemistry
Consecutive transverse cryosections from ambulatory and 7
days tail-suspended rats, transfected or co-transfected with
melusin cDNA or EV, and DN-kinase constructs, or pTGrp94
or pT, or infected with AAV-MEL or AAV-EV, were processed
for indirect immunoperoxidase using antibodies specific for
c-myc and HA tags, or EGFP and GFP proteins (Invitrogen)
as primary antibodies. Bound antibodies were revealed as
previously described .5 Additional consecutive sections were
labelled for embryonic myosin (My) using BF-G6 mAb, to dis-
criminate between adult atrophic myofibers from injection-
induced regenerating ones, or for slow My, using BA-D5
mAb, to distinguish between slow and fast myofibers.5
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Myofiber size was evaluated by measuring CSA. In some
cases, measurements were repeated using minimal Feret’s di-
ameter to exclude overestimation secondary to sample mis-
orientation.7,30 The CSA value for each myofiber population
(transfected–untransfected ones) corresponded to the mean
of the values measured from more than 100 fibers of the
same unloaded muscle (the experimental unit) and was
expressed in μm2.
NADPH-diaphorase histochemistry
Histochemistry for NADPH-diaphorase to reveal distribution
of active nNOS molecules was performed on
paraformaldehyde-fixed cryosections following the previously
described protocol.5,7 Percentage of myofiber stained sarco-
lemma was calculated by expressing the length of NADPH-d
positive sarcolemma relative to myofiber cross-sectional
circumference.
DNPH immunohistochemistry
Demonstration of myofiber carbonylation by formation of
DNPH adducts was performed on freshly cut cryosections as
previously described.5 In brief, cryosections were derivatized
with DNPH diluted 1:10 (Oxyblot Oxidized Protein Detection
Kit, Millipore) and, after saturation, incubated with anti-
DNPH antibodies. Bound antibody was revealed by subse-
quent incubation with peroxidase-conjugated secondary anti-
bodies and developed with diaminobenzidine.
Slides were observed with a Leitz Axioplan optic micro-
scope. All morphometric analyses were performed on micro-
graphs, obtained the same day from cryosections of different
samples stained on the same glass slide together with sections
from a control sample. All measurements were performed in-
dependently by two investigators using ImageJ software.
Contractile properties of soleus muscle
The experiments were performed in vitro as previously de-
scribed,9,31 using a vertical muscle apparatus (300B, Aurora
Scientific Inc.) containing a Ringer solution of the following
composition: 120 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2,
3.15 mM MgCl2, 1.3 mM NaH2PO4, 25 mM NaHCO3, 11
mM glucose, 30 μM d-tubocurarine, and pH 7.2–7.4, 30 °C,
bubbled with 95% O2–5% CO2. Muscles were stretched to
the optimal length (i.e. the length that allowed maximal ten-
sion development in response to a single pulse) and electri-
cally stimulated, by two parallel electrodes, with
supramaximal pulses (0.5 ms duration) delivered by a Grass
S44 electronic stimulator through a stimulus isolation unit
(Grass SIU5). Muscle response was recorded through an iso-
metric force transducer (Harvard) connected to an AT-MIO
16AD acquisition card (National Instruments), and data were
analysed by a specific module of the National Instruments
LabVIEW software. Twitch and tetanic tensions were normal-
ized to the muscle wet weight (specific tension, Nxg-1).
Tetanic stimulation was obtained by applying trains of
supramaximal stimuli at 80 Hz frequency. Maximum rate of
rise of tetanus was also measured (Vmax) (N/s).
Electrophoretic separation of myosin heavy chains
Analysis of My heavy chain isoforms was performed by the
SDS-PAGE method previously described, which allows separa-
tion of slow from fast My isoforms.31 Cryosections of soleus
muscles were homogenized and solubilized in SDS-PAGE sam-
ple buffer (62.5 mM Tris, pH 6.8, 2.3% SDS, 5% 2-
mercaptoethanol, 10% glycerol). Muscle protein samples (10
μg each) were electrophoresed on 8% SDS-PAGE slab gels.
Electrophoresis was run for 42 h at 70Volt constant. My
heavy chain protein bands were revealed by Colloidal
Coomassie blue staining. Isoform percentage composition
was determined by densitometry of gels.
Statistical analysis
The experimental unit corresponded to the
ambulatory/unloaded muscle. Data were expressed as mean,
median, and 5th–95th percentiles with outliers, when using
box plots representation, and as mean + SEM, when using
histograms.
Statistical analysis between two groups was performed uti-
lizing Student’s t-test. Paired Student’s t-test analysis was used
when comparing average CSA or minimal Feret’s diameter
values or percentage of FoxO3-positive myonuclei between
transfected and untransfectedmyofibers of the samemuscles.
One-way repeated measure analysis of variance (ANOVA) or
within-subject ANOVA, and Tukey or Bonferroni test for post
hoc analysis, respectively, were used for multiple comparison.
In the case of within-subject ANOVA, average values of
transfected and untransfected myofibers were compared with
values obtained from transfected muscles obtained from ani-
mals of the same body weight (matched participants). Human
data were analysed using within-subject ANOVA with time as
repeated factor. Post hoc Bonferroni tests were performed
to assess specific differences between times.
0.05 was set as the limit for significance.
Graphs were prepared using the SigmaPlot version 2.0
software (Jandel Europe, Germany).
Results
Melusin protein and mRNA levels are differently
affected by hindlimb unloading
Our experimental model of rat tail suspension induced a sta-
tistically significant decrease in soleus muscle mass
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Figure 1 (A) Left panels: representative western blot of whole homogenates from the midbelly region of ambulatory soleus muscle (A) and unloaded
(U) ones for 1–4 days, stained with anti-melusin (mel) antibodies. Red Ponceau staining of serum albumin (SA) and western blot for GAPDH are shown
as loading reference. Right panel illustrates box plots with mean (dotted) and median (solid) values of normalized melusin protein levels; n indicates the
number of animals examined. Single asterisk indicates significant difference to A, U4, U2, and U15 values; double asterisk indicates difference vs. all
values except U15; triple asterisk indicates significant difference vs. all; # indicates significant difference to A, U4, and U2; § indicates significant dif-
ference vs. all values, except U2 (P < 0.001, ANOVA). (B) Histograms show mean and SEM values of normalized melusin mRNA levels from A and U
muscles examined at each time point (ANOVA, P = 0.001). Asterisks indicate significant difference vs. all. (C) Representative western blot analysis with
rabbit polyclonal anti-β1D integrin antibodies (β1D int, upper panel) and GAPDH (lower panel) on total lysates from A and U muscles. (D) Represen-
tative confocal micrographs of double immunofluorescence with anti-melusin mAb (left column), anti-β1D integrin pAb (middle column), and merged
images (right column) on longitudinal cryosections of ambulatory (A) soleus muscle and after 6 h (U6h) and 1 day unloading (U1). Bar: 10 μm.
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normalized to body weight (MW/BW), which reached 28%
and 40% after 7 and 15 days of unloading, respectively, as
previously described7,28 and detailed in Supporting Informa-
tion, Table S1. The unloading-induced decrease in MW/BW
and myofiber CSA was apparent only after 2 days of
unloading (U2), as reported after extensive analyses which
excluded the occurrence of statistically significant myofiber
atrophy at 1 day of unloading (U1) (see figure 2 in Lechado
i Terradas et al. 7).
Unloading significantly reduced melusin protein levels be-
low 50% ambulatory levels well before muscle atrophy onset,
that is, already after a 6 h unloading bout (U6h), as demon-
strated by western blotting analyses and normalization
with two different loading controls, such as SA and GAPDH
(Figure 1A and Supporting Information, Figure S1). Although
the relative protein level of melusin appeared always signifi-
cantly reduced during unloading compared with ambulatory
values, it showed a transient, but statistically significant, stron-
ger decrease at U2 (ANOVA, P < 0.0001 and <0.005, after SA
and GAPDH normalization, respectively) and again at U15.
Quantification of melusin transcripts by quantitative real time
PCR showed a significant, transient decrease in mRNA accu-
mulation in U4 muscles compared with ambulatory and U1
muscles and a significant increase compared with both ambu-
latory and U1 levels at U7 (ANOVA, P = 0.001, Figure 1B).
At variance with melusin, protein levels of the β1D subunit
of muscle integrin did not vary during unloading, as shown by
densitometric analyses of parallel western blots (Figure 1C,
ANOVA, P = 0.56; n = 5). Such a result was confirmed by con-
focal microscopy studies (Figure 1D). In the ambulatory so-
leus, labelling for either β1D integrin or melusin was
detectable in all the myofibers32 (not shown and Supporting
Information, Figure S2). In longitudinally cut cryosections,
both proteins were detected in the correspondence of the
Z-line12,33,34, although in the absence of clear-cut signs of
co-localization. While the distribution of β1D integrin labelling
did not change during unloading, melusin staining along the
Z-line decreased strongly already in U6h muscles to disappear
almost completely in U1 and U7 muscles (Figure 1D and not
shown).
Similarly, to rat soleus during unloading,melusin protein levels
significantly decreased about 35% in human vastus lateralis biop-
sies after 1week bed rest (T8) (within-subject ANOVA, P< 0.05,
n = 8; Figure 2), that is, still in the absence of myofiber atro-
phy,7,28 comparedwith pre-bed rest levels (T0), whereas they ap-
parently returned to pre-bed rest levels at T35.
Exogenous melusin expression attenuates myofiber
atrophy and loss of force of the unloaded soleus
muscle
In order to determine whether the exogenous replacement of
melusin counteracted the atrophy of unloaded myofibers, rat
soleus muscles were co-trasfected with either a c-myc-tagged
melusin construct or EV, and a GFP-expressing vector, in or-
der to facilitate the identification of transfected myofibers.
Rats were then let free to ambulate or hindlimb unloaded
for 7 days (Figures 3A and 3B). Results show that unloaded
myofibers expressing exogenous melusin displayed a signifi-
cantly larger CSA, compared with both untrasfected and EV
transfected ones (ANOVA, P = 0.001, Figures 3C and 3D),
myofiber atrophy being attenuated from about 48% to
31%. Apparently, transfection of exogenous melusin in am-
bulatory soleus did not affect myofiber size (Figure 3C).
To ascertain whether the anti-atrophic effects of exoge-
nous melusin attenuated the loss in contractile force of
unloaded muscles too, soleus muscles were infected with ei-
ther AAV-MEL, or AAV-EV, or saline, before exposure to 7
days of hindlimb unloading. We used an AAV-MEL MOI dos-
age which significantly raised mean total melusin levels of
U7muscles compared with sham-infected or AAV-EV-infected
U7 ones (ANOVA, P = 0.01, Figure 4A), but within levels com-
parable with those observed in sham-infected ambulatory
Figure 2 (A) Representative western blot of whole homogenates from
vastus lateralis biopsies obtained from three voluntaries (P3, P4, and
P5) before (T0) and after 8 days (T8) and 35 days (T35) of bed rest,
stained with anti-melusin (mel) antibodies. Red Ponceau staining of actin
is shown as loading reference. (B) Scatter plot illustrates values of nor-
malized melusin protein levels detected in each biopsy. Asterisk indicates
significant difference vs. the corresponding T0 value (P < 0.05, within-
subject ANOVA).
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soleus. In fact, mean and SEM of normalized relative melusin
levels of unloaded AAV-MEL-infected muscles and ambula-
tory sham-infected and EV-infected ones (n = 4 for each
group) were 0.77 ± 0.11, 0.80 ± 0.13, and 0.77 ± 0.15, respec-
tively. Infection with AAV-MEL apparently involved every
muscle fiber and significantly increased MW/BW (Supporting
Information, Table S1) and CSA of U7 muscles compared with
sham-infected and EV-infected ones (Figure 4B; P ≤ 0.01,
ANOVA), without apparently affecting the relative percentage
of fast and slow fiber populations and My heavy chains
(Supporting Information, Figure S3).
Mechanical studies performed in unloaded muscles
showed that infection with AAV-MEL significantly amelio-
rated force development, because higher twitch and tetanic
tensions were observed after normalization with MW
(ANOVA, P = 0.03 and 0.05, for twitch tension and tetanic
one, respectively, Figure 4B). In addition, the infection with
AAV-MEL also significantly ameliorated the maximum rate
of rise of tetanus (Vmax) of U7 soleus muscle. In fact, Vmax
of ambulatory soleus was 3.65 ± 0.29 N/s and significantly
decreased to 1.43 ± 0.15 N/s (P < 0.001) in U7 and recov-
ered to 2.56 ± 0.20 N/s (P < 0.001) in AAV-MEL treated
U7 muscles.
Melusin pro-trophic effect is independent from
kinase pathways
Melusin, as a member of the integrin signalling machinery,33
is involved in the activation of several kinases, among which
Akt and ERK1/2, in addition to bind others, such as FAK15,18.
Unloading significantly reduces Akt, ERK1/2, and FAK activa-
tion.35–37 We found that Akt phosphorylation at Ser473 sig-
nificantly decreased after 24–48 h of unloading compared
Figure 3 (A) Representative micrographs of 7 day unloaded rat soleus muscle (U7) co-transfected with either melusin cDNA or empty vector (EV) and a
GFP-expressing construct (green fluorescence) labelled in immunofluorescence with anti-dystrophin antibodies (red fluorescence). Asterisk and thin
arrow indicate representative transfected and untransfected myofibers, respectively. Bar: 100 μm. (B) Representative micrographs of another U7mus-
cle co-transfected with melusin cDNA and the GFP-expressing construct. Myofiber transfection is revealed through labelling for either the c-myc tag
(left panel) or GFP fluorescence (right panel). Thin arrows indicate the presence of both constructs in the same transfected myofibers. Bar: 100
μm. (C) Histograms show mean and SE values of myofiber cross-sectional area (CSA) in ambulatory (A) and 7 days unloaded (U7) muscles after trans-
fection with either melusin cDNA or EV. GFP+ and GFP indicate the presence and the absence of transfected cDNAs, respectively; n indicates the
number of muscles examined; at least 100 fibers were measured for group in each muscle. Single asterisk indicates the presence of significant differ-
ence vs. A; double asterisks indicate the presence of significant difference vs. all values (within-subject ANOVA and Bonferroni’s post hoc test,
*
P <
0.005 and **P < 0.05, respectively). (D) Distribution analyses of CSA values of melusin-transfected myofibers (n = 633; black bars) and of untransfected
ones (n = 595; grey bars) in U7 unloaded soleus muscles (n = 6).
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with ambulatory muscles, whereas it apparently returned to
ambulatory levels since U4 (ANOVA, P < 0.01; Figure 5A).
Comparably, ERK1/2 activation appeared significantly
inhibited early after unloading, whereas it did not differ from
physiological levels at U4 (ANOVA, P = 0.04; Figure 5B).
We then hypothesized that the unloading-induced loss of
kinase activation might be consequent to the decrease of
melusin protein levels. To ascertain whether exogenous
melusin replacement attenuated unloading-induced myofiber
atrophy by counteracting kinase inactivation, constructs
Figure 4 (A) Left panels: western blot stained for total melusin (mel) representatively illustrates the reactivity of ambulatory soleus muscles (A) and 7
days of unloading (U7) ones after sham infection, or infection with AAV expressing melusin (AAV-MEL) or empty vector (AAV-EV). Red Ponceau staining
of serum albumin (SA) is shown as loading reference. Right panel illustrates box plots with mean (dotted) and median (solid) values of normalized total
melusin protein levels in U7muscles; n indicates the number of examined muscles. Single asterisk indicates significant difference vs. sham-infected and
AAV-EV-infected muscles (P = 0.01, ANOVA). (B) Left panels: representative micrographs of consecutive cryosections U7muscles infected with AAV-MEL
or AAV-EV. Upper panels show double labelling with anti-c-myc antibody (green fluorescence) and anti-dystrophin antibodies (red fluorescence); lower
panels show immunoperoxidase staining with anti-slow myosin (My) antibody (dark fibers). Bar: 100 μm. Right panel shows box plots of cross-sectional
area (CSA) of slow and fast myofibers in sham-infected, AAV-MEL-infected, and AAV-EV-infectedmuscles after 7 days of unloading. Solid and dotted lines
in boxes indicate median and mean values, respectively; n indicates the number of muscles examined; at least 100 fibers were measured for group in
each muscle. Single asterisk indicates the presence of significant difference vs. sham and AAV-EV values of the same fiber population (ANOVA, P = 0.001
and 0.01 for slow and fast fibers, respectively). (C) Box plots showmean (dotted) and median (solid) values of normalized twitch and tetanic tension, left
and right panels, respectively, in U7muscles after sham infection, infection with AAV-EV or with AAV-MEL; n indicates the number of examined muscles.
Single asterisk indicates the presence of significant difference vs. sham-infected muscles (P = 0.03 and 0.05, respectively, ANOVA).
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codifying for HA-tagged or GFP-tagged DN-Akt, DN-ERK, and
DN-FAK were transfected alone or in combination with hu-
man melusin cDNA in the soleus muscle, and rats were
hindlimb unloaded for 7 days (Figures 5C and 5D). CSA mea-
surements showed that positive myofibers for both exoge-
nous melusin and each DN-kinase appeared larger than
adjacent untrasfected ones or those transfected with DN-
kinase only (within-subject ANOVA for DN-Akt and melusin
co-transfections vs. untransfected and DN-Akt-transfected
unloaded myofibers, P < 0.001, Figure 5C; paired and un-
paired Student’s t-test analyses for either DN-ERK or DN-
FAK and melusin co-transfected unloaded myofibers vs.
untransfected ones, P < 0.01, Figure 5D). Comparable results
were obtained when minimal Feret’s diameter was used to
evaluate myofiber size (28.85 ± 0.78 and 24.75 ± 1.32 μm,
mean and SEM values for DN-FAK and melusin co-transfected
unloaded myofibers and untransfected ones, respectively, n
of muscles = 3; paired and unpaired Student’s t-test analysis,
P ≤ 0.03). The possibility that DN-kinase forms did not blunt
exogenous melusin effects on myofiber CSA, because of in-
creased kinase protein levels secondary to melusin expres-
sion, was excluded by comparing protein kinase total
amounts among sham-infected U7 muscles, and AAV-MEL-
infected and AAV-EV-infected ones. No difference was de-
tectable (Supporting Information, Figure S4).
Melusin pro-trophic effect does not interfere with
nNOS/FoxO3/Grp94 pathway and is synergistically
increased by NOS inhibition or Grp94/gp96
overexpression
We therefore investigated whether exogenous melusin ex-
pression counteracted the effects of other recognized pro-
atrophic drivers, such as the loss of nNOS sarcolemmal activ-
ity and localization, and atrogene activation by nuclear FoxO3
translocation (Figures 6A and 6B). NADPH-d histochemistry
was performed to investigate myofiber subcellular distribu-
tion of active nNOS molecules in melusin-transfected U7
muscles. Apparently, no difference was detectable between
melusin-transfected unloaded myofibers and untransfected
ones (Figures 6A). Measurements of NADPH-d reactivity at
sarcolemma showed that melusin-transfected myofibers
displayed even a slightly but significantly reduced percentage
of labelled cross-sectional sarcolemma than untransfected
ones (mean and SEM 30.76 ± 3.52% and 33.46 ± 3.36%, for
melusin-transfected and untransfected myofibers, respec-
tively, n = 3 muscles examined; P = 0.04, paired Student’s t-
test). It is likely that such a further reduction in sarcolemmal
nNOS activity reflects the increase in myofiber cross-sectional
sarcolemma consequent to the pro-trophic effect of
exogenus melusin expression.
The possible interference of melusin transfection with the
unloading-induced activation of the FoxO3 transcription
factor was addressed by measuring the percentage of
FoxO3-positive myonuclei relative to total myonuclei of
melusin-transfected myofibers and untransfected or EV
transfected ones (Figure 6B). Results showed that melusin
transfection did not affect unloading-induced myonuclear
translocation of FoxO3, mean and SEM values for the per-
centage of FoxO3-positive myonuclei being 61.50 ± 4.72 and
58.20 ± 5.53, for transfected myofibers and untransfected
ones, respectively (n = 5 muscles examined; more than 100
myonuclei investigated for muscle, P = 0.33, paired Student’s
t-test).
We then analysed whether and how exogenous melusin af-
fected the atrogene expression (Figures 6C and 6D). Quanti-
tative PCR investigations on the transcription factors FoxO1
and FoxO3 and the ubiquitin-ligases Atrogin-1 and MuRF-1
showed that each atrogene transcript significantly increased
in soleus muscle during unloading, although with variable ki-
netic (ANOVA, P ≤ 0.002, Supporting Information, Figure S5)
and that FoxO1, Atrogin-1, and MuRF-1 transcripts were all
significantly upregulated at U7. Expression of exogenous
melusin after AAV infection fully abolished Atrogin-1 tran-
script accumulation in U7 muscles and significantly reduced
MuRF-1 transcript levels, compared with U7 muscles infected
with AAV-EV (ANOVA, P ≤ 0.002, Figure 6C). Conversely, it ap-
parently did not hamper FoxO1 transcript accumulation.
Strikingly, but not in a statistical significant manner, expres-
sion of exogenous melusin in U7 muscles perturbed FoxO3
transcript levels, which failed to return at ambulatory levels
(Figure 6C and Supporting Information, Figure S5).
Western botting analyses were then performed to clarify
whether the perturbation of FoxO3 transcript downregula-
tion in unloaded AAV-MEL muscles corresponded to in-
creased protein levels (Figure 6D). Results showed that the
relative amount of FoxO3 protein levels was about two-fold
higher in melusin-expressing U7 muscles (Student’s t-test, P
= 0.03).
To further prove the independence between melusin and
the pathway involving nNOS/FoxO3, we investigated whether
already known antagonists of this pathway, that is, 7-NI treat-
ment or curcumin administration, counteracted the
unloading-induced melusin loss. Results showed that melusin
protein levels appeared still significantly decreased in U7
muscles either after treatment with 7-NI or with curcumin
(Figure 6C, ANOVA, P = 0.01), that is, despite of the attenua-
tion of muscle atrophy consequent to each treatment
(Supporting Information, Table S1, for 7-NI-treated rats and
figure 2 in Vitadello et al.9 for curcumin treatment).
Conversely, transfection of exogenous melusin either in
combination with 7-NI treatment (Figure 7A) or with co-
electroporation with Grp94/gp96 cDNA (Figure 7B) fully an-
tagonized myofiber atrophy of U7 soleus muscles, compared
with the attenuation obtained after NOS inhibitor administra-
tion or exogenous melusin expression alone (ANOVA, P <
0.001; compare also with figures 2C and 7C in Vitadello et al.
Melusin is involved in disuse muscle atrophy 811
Journal of Cachexia, Sarcopenia and Muscle 2020; 11: 802–819
DOI: 10.1002/jcsm.12546
Figure 5 (A) Upper panels show a representative western blot of whole homogenates from ambulatory soleus muscle (A) and unloaded (U) ones for 1–4
days, stained with anti-P-Akt and total Akt antibodies. Lower panel illustrates box plots withmean (dotted) andmedian (solid) values of P-Akt/Akt ratio; n
indicates the number of animals examined (P < 0.01, ANOVA). Single asterisk indicates significant difference vs. A values; double asterisk indicates dif-
ference vs. A, U6h, U4, and U7 values. (B) Upper panels show representative western blots of two parallel gels loaded with whole homogenates from the
same A and U muscles and stained with anti-P-ERK and total ERK antibodies, respectively. Lower panel illustrates box plots with mean (dotted) and me-
dian (solid) values of P-ERK/ERK ratio; n indicates the number of animals examined (P = 0.04, ANOVA). Single asterisk indicates significant difference vs. A
values. (C) Upper panels show indirect immunoperoxidase of consecutive cryosections from a 7 day unloaded soleus co-transfected with DN-AKT and
melusin cDNA and stainedwith anti-tag antibodies (HA for DN-AKT or c-myc formelusin). Asterisk indicates a representative doubly transfectedmyofiber.
Bar: 50 μm. Lower panel: histograms showmean and SEM values of myofiber cross-sectional area (CSA) measured in positive and negative myofiber pop-
ulations of U7muscles transfectedwith both constructs or with DN-Akt only; n indicates the number ofmuscles examined. About 100myofibers for group
were considered for muscle. Asterisk indicates significant difference vs. all (P < 0.001, within-subject ANOVA). (D) Upper panels show indirect
immunoperoxidase of consecutive cryosections from a 7 day unloaded soleus co-transfected with DN-ERK and melusin cDNA, stained with anti-tag an-
tibodies (HA for DN-ERKD or c-myc for melusin). Asterisk indicates a representative doubly transfected myofiber. Bar: 50 μm. Lower panel: histograms
showmean and SEM values of myofiber CSAmeasured in positive and negative slowmyofiber populations of U7muscles doubly transfected withmelusin
cDNA and either DN-ERK or DN-FAK; n indicates the number of muscles examined. About 100myofibers for group were considered for each muscle. As-
terisks indicate significant difference vs. untransfected myofibers (P < 0.01 paired Student’s t-test).
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Figure 6 (A) Representative sarcolemmal distribution of active nNOS by means of NADPH-d histochemistry (upper panel) in melusin-transfected 7 day
unloaded (U7) soleus. Transfected myofibers were identified using anti-tag c-myc immunoperoxidase in a consecutive cryosection (lower panel). As-
terisk identifies a transfected myofiber, whereas the void circle an untransfected one. Blue formazan staining of sarcolemma is greatly reduced in both
transfected and untransfected myofibers. Bar: 100 μm. (B) Immunofluorescence micrographs from a representative U7 melusin-transfected soleus.
The upper left panel shows the staining with anti-FoxO3 antibody and DAPI (red and blue fluorescence, respectively), whereas the upper right panel
shows green fluorescence corresponding to stainings of c-myc tag and α-sarcoglycan (the former labels myofibers expressing exogenous melusin and
the latter labels sarcolemma). The lower panel shows the merge of all the stainings. FoxO3-positive nuclei appear pink in the left panel and their
myonuclear nature is revealed after merge of all the stainings (arrows). Asterisk indicates a representative transfected myofiber. Bar: 50 μm. (C)
Dot plots show normalized values of four atrogene transcript amount detected in ambulant (A) or sham-infected, AAV-EV-infected, and AAV-MEL-in-
fected U7 muscles. No significant differences were present for FoxO1 (P = 0.07 or ns, ANOVA) and FoxO3 (P = 0.14 or ns, ANOVA), while Atrogin-1 (P =
0.0013, ANOVA; post hoc Tukey’s test, P = 0.0012, between EV and MEL) and MuRF-1 (P < 0.0001, ANOVA; post hoc Tukey’s test, P = 0.0002, between
EV and MEL) showed significantly reduced levels in MEL-infected muscles compared with EV ones. Bars in graphs represent standard errors, and as-
terisks indicate the presence of significant difference (**P < 0.01 and ***P < 0.001). (D) Upper panels: western blots of U7 muscles infected with AAV-
EV or AAV-MEL labelled with FoxO3 antibodies. Red Ponceau staining of serum albumin (SA) and western blot for GAPDH are shown as loading refer-
ence. Lower panel shows box plots of values of normalized FoxO3 protein levels. Mean and median values are indicated by a dotted and solid line,
respectively; n indicates the number of muscles examined. Asterisks indicate significant difference (P = 0.03, Student’s t-test). (E) Left panels: repre-
sentative western blots of A and U7 muscles after treatment with 7-nitroindazole (7-NI; upper panels) or curcumin (Cu; lower panels) stained with
anti-melusin antibodies (mel). Red Ponceau staining of serum albumin (SA) is shown as loading reference. Right panel shows histograms of mean
and SEM values of normalized melusin protein levels in the different conditions; n indicates the number of muscle examined. Asterisks indicate signif-
icant difference vs. ambulatory muscles (P = 0.01, ANOVA).
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5), because myofiber size of U7 soleus after each double
treatment did not show statistically significant difference
from untransfected myofibers of ambulatory muscles (Figures
7A and 7B).
Because we demonstrated that unloading-induced activa-
tion of the nNOS/FoxO3 pathway requires a mitochondrial-
derived increase in oxidative stress,7 we investigated whether
melusin expression levels affected unloading-induced oxida-
tive stress or were influenced by it. Transfection with exoge-
nous melusin did not apparently counteract myofiber
carbonylation of U7 muscles, because the percentage of
myofibers reactive for DNPH adducts were comparable be-
tween melusin-transfected and untransfected myofiber pop-
ulations (Figure 7C; mean and SEM values of DNPH-positive
myofiber percentage 20.0 ± 4.8% and 23.2 ± 4.2% for
melusin-transfected myofibers and untransfected ones, re-
spectively, n = 3 muscles, about 100 fibers evaluated for each
muscle, paired Student’s t-test, P = 0.11). On the other hand,
mitochondrial oxidative stress induced by a 6 h unloading
bout did not appear to be responsible for the early decrease
in melusin protein amount (Figure 7D). In fact, treatment
with MitoTEMPO, a specific antagonist of mitochondria-
derived oxidants, did not counteract the unloading-induced
decrease in melusin protein levels (mean and SEM values of
melusin densitometric levels normalized to SA signal were
0.28 ≤ 0.08 and 0.40± 0.05 for U6h MitoTEMPO treated (n
= 6) and untreated muscles (n = 4), respectively, Student’s
t-test, P = 0.41).
Discussion
This study demonstrates that (i) melusin is early involved in the
unloading-induced loss of muscle mass and force and (ii) main-
tenance of the protein at physiological levels is sufficient to
partially counteract disuse muscle atrophy. Indeed, here we
show that unloading-induced muscle atrophy results from
the early deregulation of at least two distinct, independent
pathways, that is, one leading to melusin loss and the other
raising mitochondrial oxidative stress and nNOS subcellular re-
distribution. Only interventions aimed to prevent both of them
fully counteracted the development of muscle disuse atrophy.
Our work on unloaded, yet not atrophic, soleus muscle
showed that mitochondrial-derived oxidative stress repre-
sents a required signal driving the myoplasmic redistribu-
tion of active nNOS sarcolemmal molecules, which are
determinant for FoxO3 nuclear traslocation.7 The
pioneering work of Suzuki et al.3 and our previous stud-
ies5,9 showed that unloading-induced loss of muscle mass
and force was attenuated by counteracting the activation
or the myoplasmic redistribution of nNOS molecules. Atten-
uated atrophy was detected in unloaded soleus from 7-NI-
treated rats, that is, after NOS inactivation.3,5 Comparable
attenuation of muscle force and mass loss was also ob-
tained by counteracting the unloading-induced decrease in
expression levels of the endoplasmic reticulum chaperone
Grp94, which interacts with nNOS and hampers its redistri-
bution in the myoplasm during unloading,5,9 as well as by
counteracting oxidative stress, which initiates the redistri-
bution of active nNOS molecules from sarcolemma to
myoplasm.4,7,8
Here, we identify melusin, the muscle-specific integrin-
associated protein, as a novel relevant regulator of skeletal
muscle mass and force. At variance with nNOS and Grp94,
melusin protein levels appear already significantly reduced af-
ter a 6 h unloading bout. This event occurs independently
from mitochondrial-derived oxidative stress and appears to
be post-transcriptionally regulated, because downregulation
of melusin gene transcription becomes detectable later on.
We also show here that the unloading-induced decrease in
melusin protein levels is changed neither after inhibition of
mitochondrial derived oxidative stress with MitoTEMPO, nor
of nNOS activity by means of 7-NI, nor after Grp94 upregula-
tion by curcumin administration. Because all these treat-
ments were shown to blunt FoxO3 nuclear
translocation/activity,3–5,7 we may conclude that such an
early loss of melusin protein is not the product of FoxO3-
induced atrogene activation.
Furthermore, melusin, but not β1D integrin, is lost from
costameres, the macromolecular complexes aligned between
the sarcolemma and underlying sarcomeric myofibrils coinci-
dent with Z-discs.33,34 Costameres assembly is jeopardized
by unloading, because of either decreased FAK activation37,38
or reduced expression of the kinase and its inhibitor FRNK,
which characterized human muscle already after 8 day bed
rest.39 Five days of bed rest are sufficient to downregulate
transcriptome of integrin signalling pathway in both young
and old subjects.40 Our finding that melusin, a FAK-interacting
protein, decreased early after unloading also in human mus-
cle is in line with these reports and may represent a major de-
terminant of costamere deregulation.
Indeed, prevention of melusin loss by means of exoge-
nous melusin expression had a beneficial effect in the rat
model of muscle disuse/unloading, on both the degree of
myofiber atrophy and force development. The pro-trophic
role of melusin has been extensively investigated for car-
diac myocytes, where melusin absence accelerates eccentric
left ventricle remodelling and transition toward heart fail-
ure, whereas melusin overexpression leads to compensa-
tory hypertrophy with increased pump function and
protects from dilation.16 Our findings in unloaded skeletal
muscle confirm melusin pro-trophic role and show its rele-
vant contribution to contractility. This latter effect, which
does not depend only from atrophy attenuation, might re-
sult from melusin participation to costamere structure and
role in force transmission. Indeed, costameres are hypothe-
sized to collect forces spreading laterally to the long axis of
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Figure 7 (A) Left panel: immunofluorescence micrograph from a representative U7 melusin-transfected soleus from a 7-nitroindazole (7-NI)-treated
rat stained for c-myc tag (red fluorescence), to identify melusin-transfected myofibers, and dystrophin (green fluorescence) Bar: 50 μm. Right panel
displays box plots showing mean (dotted line) and median (solid line) values of cross-sectional area (CSA) of ambulatory (A) untransfected myofibers
measured in EV transfected muscles and 7 day unloaded (U7) melusin-transfected and untransfected myofibers after treatment with 7-NI or vehicle
(OIL); n indicates the number of muscles studied. A minimum of 100 fibers was considered per group. Asterisks indicate the presence of statistically
significant difference vs. CSA values of A and 7-NI+U7mel+ (P < 0.001, ANOVA and within-subject ANOVA). Post hoc Tukey’s test: P ≤ 0.004 between A
and 7-NI+U7mel, OIL+U7mel+, OIL+U7mel; P ≤ 0.05 between 7-NI+U7mel+ and 7-NI+U7mel, OIL+U7mel+ (double asterisk); P< 0.001 between 7-
NI+U7mel+ and OIL+U7mel (single asterisk); P = 0.14 between A and 7-NI+U7mel+; post hoc paired Bonferroni’s test: P = 0.001 between 7-NI+U7mel+
and 7-NI+U7mel and between OIL+U7mel+ and OIL+U7mel (double asterisks). (B) Left panels: consecutive cryosections from U7 solei co-
transfected with melusin (mel) and Grp94 cDNA or empty vector (EV) stained in indirect immunoperoxidase with anti-tag antibodies (c-myc for melusin
and GFP for Grp94 or EV). Asterisk indicates a doubly transfected myofiber; thin arrow an untransfected myofiber. Bar: 50 μm. Right panel: histograms
show mean and SEM values of A untransfected myofibers measured in EV transfected muscles and U7 myofiber CSA, measured in doubly transfected
myofibers and untransfected ones; n indicates the number of muscles examined. At least 100 myofibers for group were considered for each muscle.
Asterisks indicate significant difference vs. CSA values of A and U7mel+Grp94+ (P < 0.001, ANOVA and within-subject ANOVA). Post hoc Tukey’s test: P
< 0.01 between A and U7melGrp94, U7mel+EV+ or U7melEV; P ≤ 0.04 between U7mel+Grp94+ and U7mel+EV+ (double asterisk); P ≤ 0.002
between U7mel+Grp94+ and U7melGrp94, or U7melEV (single asterisk); P = 0.22 between A and U7mel+Grp94+; post hoc paired Bonferroni’s
test: P ≤ 0.005 between U7mel+Grp94+ and U7melGrp94 and between U7mel+EV+ and U7melEV (single asterisks). (C) Consecutive cryosec-
tions from U7 melusin-transfected soleus stained in indirect immunoperoxidase with anti-tag antibodies (anti-DNPH for carbonylated adducts and
anti-c-myc for melusin). Thin arrow indicates a carbonylated transfected myofiber; large arrow a carbonylated untransfected one. Bar: 50 μm. (D)
Western blot of ambulatory soleus muscles (A) and unloaded ones for 6 h (U6h) in the absence or in the presence of treatment with MitoTEMPO
(MT) stained with anti-melusin antibodies (mel). Red Ponceau staining of serum albumin (SA) is shown as loading reference.
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the sarcomere, from each myofibril to the neighbouring
one, and to channel them across the sarcolemma to the
extracellular matrix, by providing up to 70% of the muscle
contraction force.41 Thus, the stabilization of the costamere
and, as a consequence, of the sarcomere structure and
myofilament relationships may explain the attenuated loss
of muscle force and contractility. Alternatively, exogenous
melusin effects on unloaded muscle contractility may come
through the contribution of other proteins. Among possible
candidates, Hsp70 was shown to be upregulated in con-
comitance with melusin overexpression in cardiomyocytes21
and effective in counteracting unloading/disuse-induced
loss of muscle mass and force.42–47 However, such a possi-
bility is apparently excluded here by the lack of significant
changes in Hsp70 protein levels in both ambulatory and
unloaded AAV-MEL-infected muscles compared with AAV-
EV and sham-infected ones (L. Gorza, unpublished
observations).
In addition to contractility, exogenous melusin attenu-
ated the unloading-induced loss in myofiber size. Melusin
pro-trophic effect occurred acting on ubiquitin-ligase ex-
pression, that is, exogenous melusin expression blunted
unloading-induced Atrogin-1 transcript accumulation and
reduced, without silencing, MurRF-1 one. Strikingly, such a
downregulation occurred in the presence of deregulation
of their major inductor FoxO3,48 whose protein levels were
still significantly higher after 7 days of unloading and main-
tained a myonuclear localization. Such a result strongly sug-
gests that melusin replacement does not act by silencing
FoxO3 signalling pathway. Indeed, exogenous melusin did
not hamper nNOS subcellular relocalization or oxidative
stress, leading to myofiber carbonylation, two major up-
stream regulators of FoxO3 activation in the disused mus-
cle.3,5,7 Similarly, melusin replacement apparently did not
act through the interaction with FAK and the activation of
downstream kinases such as Akt and ERK1/2,12,16,18 which
represent relevant inhibitors of FoxO3 transcriptional acti-
vation,49–51 because co-transfection of melusin cDNA with
defective forms of these kinases did not abolish its pro-
trophic effect. Attenuation of myofiber atrophy by exoge-
nous melusin did not result from the activation of
Akt/mTOR/S6K pathway,35,52 nor it depended from the par-
allel activation of the 90 kDa ribosomal S6 kinase, by
means of phosphorylation by ERK2 after binding at the D-
domain .25,52 Therefore, if FoxO3 is still upregulated and
transcriptionally active, the demonstration of Atrogin-1 si-
lencing and a significant, albeit not complete, MuRF-1
downregulation suggests the interference of a different
pro-trophic pathway. This possibility is consistent with liter-
ature evidence indicating that Atrogin-1 regulation may oc-
cur independently from FoxO3 activation.48,53 Therefore,
still unknown partners are expected to mediate exogenous
melusin signalling leading to Atrogin-1 silencing in the
unloaded soleus muscle.
Consistent with such a hypothesis is the evidence that
melusin transfection combined with interventions aimed to
block nNOS/FoxO3/Grp94 deregulation, such as treatment
with the NOS inhibitor 7-NI or co-transfection with Grp94,
fully counteracted myofiber atrophy in U7 soleus muscle, im-
plying that both nNOS/Grp94 and melusin are required, be-
cause they are independently involved in the maintenance
of myofiber size challenged by muscle unloading/disuse.
The possibility that the full pro-trophic effect resulted
from downstream complementation between the two path-
ways has to be considered too. Increased Grp94 levels may
enhance folding and maturation of IGFI and II,54 which
would act on potentiated IGF receptors by a restored
integrin signalling after exogenous melusin expression55
and, therefore, abolish myofiber atrophy. However, such a
possibility is supported neither by the lack of significant de-
crease in IGFI and IGFII protein levels in our unloaded mus-
cles5 nor by the absence of effects of 7-NI treatment on
the unloaded-induced decrease of Grp94 protein amount
(L. Gorza, unpublished observations). Therefore, our body
of evidence indicates melusin as a nNOS/Grp94-
independent player.
Although both nNOS and melusin are costamere proteins,
unloading-induced, mitochondrial-derived oxidative stress ini-
tiates nNOS redistribution in the sarcoplasm,7 whereas it
does not appear involved in melusin protein decrease. A
short unloading bout induces also disorganization in the
lipid-ordered phase of sarcolemma,56 detachment of cyto-
skeletal components, such as the non-muscle α-actinin iso-
form 4,57 and loss of function of α2Na-K-ATPase pump.
58 It
remains to be determined whether any of these unloading-
induced perturbations would act upstream or downstream
melusin loss from costameres and catabolism.
In conclusion, this study shows that disuse muscle atrophy
results from the deregulation of at least two master switches,
melusin and nNOS, only the latter being oxidative stress de-
pendent. In both humans and experimental laboratory ani-
mals, the loss of active nNOS molecules from sarcolemma
and the decreased melusin amount represent very early
events in the development of disuse muscle atrophy. In spite
of the desire to uncover a single master regulatory switch,
here we demonstrate that unloading-induced muscle atrophy
can be abolished only by addressing simultaneously melusin
and nNOS deregulations.
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Figure S1. A) Representative Western blot of whole homoge-
nates from the midbelly region of ambulatory soleus muscle
(A) and unloaded (U) ones for 4 days (left panels) and 7 days
(right panels), stained with anti-melusin (mel) antibodies. Red
Ponceau staining of serum albumin (SA) and Western blot for
GAPDH are shown as loading reference. B) Box plots with
mean (dotted) and median (solid) values of normalized
melusin protein levels to GAPDH. n indicates the number of
animals examined. Single asterisk indicates significant differ-
ence to A values; double asterisk indicates significant differ-
ence to A and U6h. (P < 0.005 ANOVA).
Figure S2. Transverse consecutive cryosections from ambula-
tory rat soleus muscle stained for immunoperoxidase with
anti-melusin mAb (mel) and anti-slow myosin (slow-My). La-
belling for melusin is detectable in every myofiber with a
slight heterogeneity, involving mostly fast myofibers (thin ar-
row) in addition to slow myofibers (thick arrow). Bar: 50 μm
Figure S3. A) Histograms showing mean and SEM of the per-
centage of fast fibers in sham-infected ambulatory (A) and 7-
day unloaded (U) muscles and in AAV-infected 7-day U mus-
cles with melusin (U MEL) or empty virus (U EV). N indicates
the number of muscles examined. More than 200 fibers were
evaluated for muscle. ANOVA P=ns B) Upper panel shows the
Coomassie blue staining of a representative gel electrophore-
sis showing separation of myosin heavy chains (My). Slow My
migrates faster than fast My. Lower panels show histograms
of mean and SD values of the relative percentage of fast
My densitometric values on total ones. ANOVA P = ns
Figure S4. A) Representative Western blots of different whole
homogenates from 7-days unloaded soleus muscles after in-
fection with AAV (U7 + AAV) expressing melusin (MEL) or
empty vector (EV) labelled for total Akt and ERK1/2. Parallel
staining with anti-GAPDH antibodies and Red Ponceau stain-
ing of serum albumin (SA) is shown as loading reference. B)
Left and right panels illustrate histograms of mean and SEM
values of normalized total Akt protein levels with SA and
GAPDH, respectively. n indicates the number of examined
muscles. ANOVA P=ns C) Left and right panels illustrate histo-
grams of mean and SEM values of normalized total ERK1/2
protein levels with SA and GAPDH, respectively. n indicates
the number of examined muscles. ANOVA P=ns
Figure S5. Dot plots showing normalized values of four
atrogene transcript amount detected in ambulatory (A) so-
leus muscle and after 1, 4 and 7 days of unloading (U). FoxO1
(P<0.0001, ANOVA; post-hoc Tukey’s test p<0.0001 be-
tween A and U7), Atrogin (P<0.0001, ANOVA; post-hoc
Tukey’s test p=0.05 between A and U7) and MufF1
(P<0.0001, ANOVA; post-hoc Tukey’s test p<0.0001 be-
tween A and U7) transcript were all significantly upregulated
at U7. Bars in graphs represent standard errors and asterisks
indicate the presence of significant difference (*p < 0.05, **p
< 0.01; ***p < 0.001).
Table S1. Body and soleus muscle weights of ambulatory and
tail-suspended rats
Table S2. Primer sets used for qPCR
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